{"Clinical Trial ID": "NCT00429572", "Intervention": ["INTERVENTION 1:", "Allogeneic replanting", "Intravenous fludarabine 30 mg/m^2 per day on days 1 to 5 and melphalan 70 mg/m^2 on days 4 and 5 followed by a blood stem cell transplant on day 7."], "Eligibility": ["Incorporation criteria:", "- Recurrent or residual metastatic breast carcinoma", "Zubrod's performance level of less than 2", "18-60 years", "A human leukocyte antigen (HLA) related donor is compatible with allogeneic transplantation or an unrelated HLA-compatible donor.", "No major organ dysfunction or active infection", "Exclusion criteria: None"], "Results": ["Performance measures:", "Number of participants who responded to the questionnaire", "The best response recorded from the start of treatment to disease progression or recurrence using the World Health Organization (WHO) comprehensive response criteria: elimination of all diseases/symptoms > 4 weeks; partial response, > 50% reduction in the sum of the products of diameter of each measurable lesion for more than 4 weeks; stable disease, no change in tumour size; and progressive disease, new lesions or > 25% increase in the sum of the products of diameter of any measurable lesion.", "Timeline: Baseline data to measure progressive disease (post-study follow-up period, 24 months from the date of last drug administration) Data collected every 4 months.", "Results 1:", "Title of the arm/group: Allogeneic Transplantation", "Description of the arm/group: Intravenous Fludarabine 30 mg/m^2 per day on days 1 to 5 and Melphalan 70 mg/m^2 on days 4 and 5 followed by a blood stem cell transplant on day 7.", "Total number of participants analysed: 18", "Type of measurement: Number", "Unit of measure: Participants Complete response: 5", "Stable disease: 9", "Partial response: 1", "Progressive diseases: 3"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/19 (0.00 per cent)"]}